Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Francisella Tularensis Infections - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Francisella Tularensis Infections - Pipeline Review, H1 2015', provides an overview of the Francisella Tularensis Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Francisella Tularensis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Francisella Tularensis Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Francisella Tularensis Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Francisella Tularensis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Francisella Tularensis Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Francisella Tularensis Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Francisella Tularensis Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Francisella Tularensis Infections Overview 7 Therapeutics Development 8 Pipeline Products for Francisella Tularensis Infections - Overview 8 Pipeline Products for Francisella Tularensis Infections - Comparative Analysis 9 Francisella Tularensis Infections - Therapeutics under Development by Companies 10 Francisella Tularensis Infections - Therapeutics under Investigation by Universities/Institutes 11 Francisella Tularensis Infections - Pipeline Products Glance 12 Early Stage Products 12 Francisella Tularensis Infections - Products under Development by Companies 13 Francisella Tularensis Infections - Products under Investigation by Universities/Institutes 14 Francisella Tularensis Infections - Companies Involved in Therapeutics Development 15 Aradigm Corporation 15 EpiVax, Inc. 16 Evolva SA 17 Tetraphase Pharmaceuticals Inc. 18 Francisella Tularensis Infections - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 ciprofloxacin hydrochloride - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 EV-009 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 francisella tularensis [strain SchuS4] vaccine - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 francisella tularensis vaccine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Monoclonal Antibodies to Inhibit EF-Tu for Francisella Tularensis Infections - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule to Inhibit Enoyl-Reductase for Bacillus Anthracis and Francisella Tularensis Infections - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules to Inhibit FtsZ Protein for Bacterial Infections - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Small Molecules to Inhibit InhA for Infectious Diseases - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Small Molecules to Inhibit Nucleolin for Oncology and Infectious Disease - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 SRI-011225 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 TP-271 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 tularemia vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 TuliVax - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Francisella Tularensis Infections - Recent Pipeline Updates 43 Francisella Tularensis Infections - Dormant Projects 44 Francisella Tularensis Infections - Discontinued Products 45 Francisella Tularensis Infections - Product Development Milestones 46 Featured News & Press Releases 46 Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables Number of Products under Development for Francisella Tularensis Infections, H1 2015 8 Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H1 2015 9 Number of Products under Development by Companies, H1 2015 10 Number of Products under Investigation by Universities/Institutes, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Francisella Tularensis Infections - Pipeline by Aradigm Corporation, H1 2015 15 Francisella Tularensis Infections - Pipeline by EpiVax, Inc., H1 2015 16 Francisella Tularensis Infections - Pipeline by Evolva SA, H1 2015 17 Francisella Tularensis Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Francisella Tularensis Infections Therapeutics - Recent Pipeline Updates, H1 2015 43 Francisella Tularensis Infections - Dormant Projects, H1 2015 44 Francisella Tularensis Infections - Discontinued Products, H1 2015 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
